NUVB
Nuvation Bio·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NUVB
Nuvation Bio Inc.
A company that developing novel therapeutic candidates for the treatment of oncology
1500 Broadway, Suite 1401, New York, New York 10036
--
Nuvation Bio Inc. was incorporated in Delaware on April 24, 2020. The company is a biopharmaceutical company that addresses some of the largest unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's patented products include mechanistically different tumor treatment products, each targeting some of the most difficult cancer types to treat.
Company Financials
EPS
NUVB has released its 2025 Q3 earnings. EPS was reported at -0.16, versus the expected -0.15, missing expectations. The chart below visualizes how NUVB has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NUVB has released its 2025 Q3 earnings report, with revenue of 13.12M, reflecting a YoY change of 1704.68%, and net profit of -55.79M, showing a YoY change of -35.38%. The Sankey diagram below clearly presents NUVB's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
